HMGB1 and COVID-19: In accordance with these pathophysiological outcomes, some conventional gargling drugs suggested in the initial treatment of COVID-19 for leading oropharyngeal viral shedding, such asAnkaferd hemostat, containGlycyrrhiza glabra, which contributes to antiinflammatory efficacy by way of a decline in the high mobility group box 1 protein [HMGB1] secretion [40].